TABLE 3.
The baseline ocular parameters and subsequent changes during the follow-up period.
| Pre lens wear | 1 month | 3 months | 6 months | 12 months | |
| SE (D), mean ± SD | −2.27 ± 1.08 | – | – | – | – |
| AL (mm), mean ± SD | 24.09 ± 0.59 | 24.12 ± 0.59 | 24.16 ± 0.60 | 24.23 ± 0.61 | 24.22 ± 0.57 |
| Corneal curvature (D), mean ± SD | 43.25 ± 1.04 | ||||
| CCT (μ m), mean ± SD | 553.71 ± 9.83 | 550.38 ± 9.72 | 554.04 ± 12.87 | 555.71 ± 10.15 | 555.69 ± 9.42 |
| CECC, mean ± SD | 2726.64 ± 270.45 | 2743.69 ± 28.47 | 2787.84 ± 101.31 | 2751.89 ± 72.38 | 2794.15 ± 87.02 |
| IOP (mmHg), mean ± SD | 15.31 ± 1.66 | 15.18 ± 1.51 | 15.00 ± 1.68 | 14.96 ± 2.01 | 15.13 ± 1.55 |
| Naked eye vision, mean ± SD | 0.74 ± 0.44 | −0.01 ± 0.02 | −0.02 ± 0.04 | −0.02 ± 0.07 | −0.03 ± 0.09 |
| OSDI score, mean ± SD | 5.36 ± 1.15 | 6.36 ± 2.52 | 7.26 ± 1.72 | 7.16 ± 2.09 | 7.42 ± 1.40 |
| TBUT (s), mean ± SD | 11.98 ± 1.08 | 11.87 ± 0.97 | 11.80 ± 1.04 | 12.00 ± 1.00 | 11.87 ± 1.16 |
| CFS score, mean ± SD | 0.24 ± 0.43 | 0.42 ± 0.54 | 0.40 ± 0.54 | 0.36 ± 0.48 | 0.38 ± 0.61 |
| f-TBUT (s), mean ± SD | 11.85 ± 0.84 | 11.93 ± 1.06 | 12.24 ± 0.79 | 11.92 ± 1.08 | 11.90 ± 1.45 |
| a-TBUT (s), mean ± SD | 13.45 ± 1.25 | 13.38 ± 1.19 | 13.56 ± 1.08 | 13.21 ± 1.23 | 13.18 ± 1.00 |
| TMH (mm), mean ± SD | 0.25 ± 0.06 | 0.24 ± 0.06 | 0.23 ± 0.05 | 0.23 ± 0.04 | 0.24 ± 0.06 |
| Final break-up areas, mean ± SD | 3.67 ± 1.98 | 4.12 ± 2.08 | 3.99 ± 2.23 | 4.11 ± 1.88 | 4.31 ± 2.24 |
| Meibomian gland loss grade, mean ± SD | 0.44 ± 0.50 | 0.42 ± 0.50 | 0.44 ± 0.50 | 0.42 ± 0.50 | 0.47 ± 0.55 |
AL, axial length; CCT, central corneal thickness; CFS, corneal fluorescein staining; D, diopter; IOP, intraocular pressure; OK, orthokeratology; OSDI, ocular surface disease index; SE, spherical equivalent; TBUT, tear break-up time; TMH, tear meniscus height.